Cai Jing Wang·2025-10-22 05:33Core Insights - The collaboration between Innovent Biologics and Takeda Pharmaceutical aims to leverage Innovent's strengths in tumor immunology (IO) and antibody-drug conjugates (ADC) alongside Takeda's extensive experience in global oncology drug development to accelerate the global development of Innovent's late-stage pipeline drugs [1] Group 1: Collaboration Details - Innovent and Takeda will jointly develop the next-generation IO cornerstone therapy IBI363 (PD-1/IL-2α-bias) and will co-commercialize it in the United States, with Takeda leading the development under a collaborative governance structure [1] - Innovent grants Takeda commercialization rights for IBI363 outside Greater China and the United States [1] - Takeda receives exclusive rights for IBI343 (CLDN18.2 ADC) outside Greater China and an exclusive option for IBI3001 (EGFR/B7H3 ADC) outside Greater China [1] Group 2: Financial Terms - Innovent will receive an upfront payment of $1.2 billion, which includes a $100 million premium strategic equity investment, along with potential milestone payments, bringing the total deal value to up to $11.4 billion [1] - Innovent will also receive a share of sales from the collaboration [1]